German Hodgkin's Lymphoma Study Group Trials: Lessons from the Past and Current Strategies-Reference-Cited by-同舟云学术

German Hodgkin's Lymphoma Study Group Trials: Lessons from the Past and Current Strategies

Published:2006-05 Issue:6 Volume:6 Page:458-468
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Draube Andreas,Behringer Karolin,Diehl Volker

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference70 articles.

1. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients;Horning;Blood,2004

2. ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial;Chisesi;Ann Oncol,2002

3. ABVD vs. STANFORD V (SV) vs. MOPP-EBV-CAD (MEC) in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial;Federico;Proc Am Soc Clin Oncol,2004

4. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease;Radford;J Clin Oncol,2002

5. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody;Schnell;J Clin Oncol,2005

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline;Haematologica;2022-05-31

2. Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis;Journal of Cancer Survivorship;2021-01-16

3. MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients;PLoS ONE;2013-05-21

4. Survival from common and rare cancers in Germany in the early 21st century;Annals of Oncology;2012-02

5. Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group;Leukemia & Lymphoma;2011-02-14